Market Overview

UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential

Related XOMA
MLV & Co Has Positive Outlook On XOMA
XOMA Posts Wider Q1 Loss - Analyst Blog

Credit Suisse initiated coverage on XOMA Corporation (NASDAQ: XOMA) with an Outperform rating and a $4 price target.

Credit Suisse commented, "Xoma has recently refocused its efforts and bolstered its balance sheet to advance the development of gevokizumab for multiple indications. Retained marketing rights, a well-designed clinical program, and multiple data readouts in the next 12 months provide for upside potential, although with speculative risk."

XOMA Corporation closed at $2.67 on Monday.

Latest Ratings for XOMA

DateFirmActionFromTo
Apr 2014McNicoll Lewis VlakUpgradesHoldBuy
Mar 2014McNicoll Lewis ValkDowngradesBuyHold
Mar 2014Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for XOMA
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (XOMA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters